The choice of tools that enable efficient targeting of exogenous antigens (Ag) for processing and presentation by professional Ag-presenting cells (APC) remains limited. This represents, indeed, a bottleneck in development of vaccines inducing specific T-cell responses. Here, we describe a novel strategy of Ag delivery into APCs. The Ag of choice is fused to the N- or C-terminus of streptavidin (SA) and tetrameric Ag-SA or SA-Ag fusion proteins are produced in E. coli and purified by 2-Iminobiotin-Agarose affinity chromatography. Alternatively, Ag-SA proteins are purified from urea extracts of E. coli inclusion bodies and refolded in vitro into functional tetramers. Complexes with biotinylated antibodies targeting cell surface receptors are formed and used to deliver the Ags of choice for processing and presentation by APCs and induction of Ag-specific CD4+ and CD8+ T-cell responses in vitro and in vivo.

Laboratory of Molecular Biology of Bacterial Pathogens Institute of Microbiology of the ASCR Videnska 1083 14220 Prague Czech Republic

Zobrazit více v PubMed

Biochem J. 1989 Apr 15;259(2):369-76 PubMed

Vaccine. 2007 Dec 12;25(51):8622-36 PubMed

Biol Chem. 2001 Apr;382(4):521-32 PubMed

Infect Immun. 1995 May;63(5):1710-7 PubMed

J Exp Med. 2004 Mar 15;199(6):815-24 PubMed

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9 PubMed

Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6020-4 PubMed

J Immunol. 2007 Jan 15;178(2):748-56 PubMed

Nat Biotechnol. 2008 Nov;26(11):1261-8 PubMed

Infect Immun. 2006 Jun;74(6):3396-407 PubMed

PLoS Pathog. 2008 Feb 8;4(2):e33 PubMed

Blood. 2006 Jul 1;108(1):328-36 PubMed

J Immunol Methods. 1999 Feb 1;223(1):77-92 PubMed

Infect Immun. 2006 Apr;74(4):2128-37 PubMed

Science. 1999 Sep 3;285(5433):1569-72 PubMed

Nat Med. 2010 Aug;16(8):915-20 PubMed

FEBS J. 2006 Apr;273(7):1445-62 PubMed

Int J Med Microbiol. 2004 Apr;293(7-8):571-6 PubMed

Clin Diagn Lab Immunol. 2000 Mar;7(2):155-60 PubMed

J Biol Chem. 1987 Oct 15;262(29):13933-7 PubMed

Int Immunol. 1994 Mar;6(3):369-76 PubMed

Drug Discov Today. 2011 Dec;16(23-24):1061-8 PubMed

Eur J Immunol. 2003 Apr;33(4):850-60 PubMed

J Biol Chem. 1995 Nov 24;270(47):28204-9 PubMed

Eur J Immunol. 2010 Jan;40(1):36-46 PubMed

Trends Immunol. 2004 Feb;25(2):92-7 PubMed

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1289-94 PubMed

Cancer Res. 2007 Sep 15;67(18):8847-55 PubMed

Vaccine. 2008 Nov 25;26(50):6433-40 PubMed

J Nucl Med. 2004 May;45(5):867-77 PubMed

Blood. 2002 Aug 1;100(3):1084-7 PubMed

J Biol Chem. 2002 Jun 14;277(24):21598-603 PubMed

Expert Opin Drug Deliv. 2006 Mar;3(2):177-90 PubMed

Vaccine. 2010 Oct 18;28(44):7146-54 PubMed

J Immunol. 1993 Jan 15;150(2):438-46 PubMed

Nat Rev Microbiol. 2007 Jul;5(7):505-17 PubMed

Cancer Res. 2000 Dec 1;60(23):6663-9 PubMed

Genet Vaccines Ther. 2003 Sep 16;1(1):2 PubMed

Eur J Immunol. 2008 Aug;38(8):2263-73 PubMed

Eur J Pharm Biopharm. 2007 Mar;65(3):398-405 PubMed

Vaccine. 2011 Mar 24;29(15):2649-52 PubMed

J Exp Med. 2002 Dec 16;196(12):1627-38 PubMed

Microbiology (Reading). 1998 Nov;144 ( Pt 11):3195-3203 PubMed

Vaccine. 2010 Oct 4;28(42):6930-41 PubMed

Mol Pharm. 2009 Jan-Feb;6(1):158-72 PubMed

Nat Rev Drug Discov. 2005 Feb;4(2):145-60 PubMed

Cytokine response to the RSV antigen delivered by dendritic cell-directed vaccination in congenic chicken lines

A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies